Abstract
Pulmonary arterial hypertension (PAH) is a chronic ailment of the lungs, exhibiting elevated arterial pressure and vascular resistance; with a mean arterial pressure above 25 mmHg at rest and above 30 mmHg during exercise. It is associated with poor prognosis, and its prevalence is estimated to be 15 cases per one million.
The current treatment options for PAH are discussed with the prostanoid class of drugs being the most effective. The latter drugs act by dilating systemic and pulmonary arterial vascular beds and, with sustained long-term usage, altering pulmonary remodelling. They are administered as IV infusions or inhalation solutions. Despite their clinical effectiveness, prostanoids have short half-lives requiring frequent administration of 6-9 times daily and thus suffer from poor compliance.
Controlled release inhalation delivery systems for treatment of PAH, ranging from liposomes, biodegradable nano and microparticles, formation of co-precipitates and complexation with cyclodextrins, are explored. Arising from these formulation strategies, we developed novel polymeric microspheres for inhalation to reduce dosing frequency and improve medication compliance. These microspheres are designed with release modifiers, to reside in the lung which is the site of drug action for a longer duration so as to release the drug slowly and consistently over a prolonged period. This could lead to the development of the first commercially available controlled release inhalation product.
Keywords: Pulmonary arterial hypertension, treatment, inhalation, controlled release, polymeric microspheres.
Current Pharmaceutical Design
Title:Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension
Volume: 21 Issue: 40
Author(s): Aparna Saigal, Wai Kiong Ng, Reginald B.H. Tan and Sui Yung Chan
Affiliation:
Keywords: Pulmonary arterial hypertension, treatment, inhalation, controlled release, polymeric microspheres.
Abstract: Pulmonary arterial hypertension (PAH) is a chronic ailment of the lungs, exhibiting elevated arterial pressure and vascular resistance; with a mean arterial pressure above 25 mmHg at rest and above 30 mmHg during exercise. It is associated with poor prognosis, and its prevalence is estimated to be 15 cases per one million.
The current treatment options for PAH are discussed with the prostanoid class of drugs being the most effective. The latter drugs act by dilating systemic and pulmonary arterial vascular beds and, with sustained long-term usage, altering pulmonary remodelling. They are administered as IV infusions or inhalation solutions. Despite their clinical effectiveness, prostanoids have short half-lives requiring frequent administration of 6-9 times daily and thus suffer from poor compliance.
Controlled release inhalation delivery systems for treatment of PAH, ranging from liposomes, biodegradable nano and microparticles, formation of co-precipitates and complexation with cyclodextrins, are explored. Arising from these formulation strategies, we developed novel polymeric microspheres for inhalation to reduce dosing frequency and improve medication compliance. These microspheres are designed with release modifiers, to reside in the lung which is the site of drug action for a longer duration so as to release the drug slowly and consistently over a prolonged period. This could lead to the development of the first commercially available controlled release inhalation product.
Export Options
About this article
Cite this article as:
Saigal Aparna, Ng Kiong Wai, Tan B.H. Reginald and Chan Yung Sui, Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension, Current Pharmaceutical Design 2015; 21 (40) . https://dx.doi.org/10.2174/1381612821666151008124451
DOI https://dx.doi.org/10.2174/1381612821666151008124451 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention (Discontinued) Current Screening Tests and Novel Early Detection Approaches for Alzheimer's Disease
Neuroscience and Biomedical Engineering (Discontinued) Helicobacter pylori Eradication Improves the Malnutrition, Inflammation and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Renal Function Impairment in Patients Undergoing Elective EVAR vs. Elective Open Repair During Follow up Period: A Systematic Review of the Literature
Current Vascular Pharmacology Caregiver Burden in Fragile X Families
Current Psychiatry Reviews Metabolic Syndrome - Risk Factors for Atherosclerosis and Diabetes
Current Diabetes Reviews Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Current Cancer Drug Targets Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts
Current Respiratory Medicine Reviews Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation
Current Drug Targets Editorial (New Wave from Immunology, Endocrine & Metabolic Agents in Medicinal Chemistr )
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Potential Utility of Telmisartan, an Angiotensin II Type 1 Receptor Blocker with Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ)-Modulating Activity for the Treatment of Cardiometabolic Disorders
Current Molecular Medicine Reactive Oxygen Species, Nitric Oxide and Hypertensive Endothelial Dysfunction
Current Hypertension Reviews Antioxidant Potentials and Xanthine Oxidase Inhibitory Effect of Two Furanocoumarins Isolated from <i>Tamus communis</i> L
Medicinal Chemistry Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Effect of Fenofibrate on the Concentration and Relative Distribution of LDL Subfractions in Patients with Combined Dyslipidemia
Letters in Drug Design & Discovery Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment
Current Alzheimer Research